Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ONCOGENEX PHARMACEUTICALS Inc OGXI

Healthcare Biotechnology
"OncoGenex Pharmaceuticals Inc is a biopharmaceutical company focused on the development of cancer treatment resistance. It has developed Apatorsen to block the production of heat shock protein 27, or Hsp27, that promotes treatment resistance in cancer."

Recent & Breaking News (NDAQ:OGXI)

OncoGenex to Present at Leerink Global Healthcare Investor Conference

PR Newswire February 6, 2014

OncoGenex to Present at Credit Suisse Healthcare Investor Conference

Canada NewsWire November 5, 2013

OncoGenex to Report Financial Results for Third Quarter 2013 and Address Key Questions from Investors on November 7, 2013

Canada NewsWire October 30, 2013

Five Corners Capital Inc. Appointed as New General Partner for Former Ventures West-Managed Funds

Marketwired October 2, 2013

OncoGenex Announces that the Rainier(TM) Clinical Trial Evaluating Apatorsen (OGX-427) in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer is Now Open for Enrollment

Canada NewsWire August 27, 2013

OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference

Canada NewsWire August 7, 2013

OncoGenex Announces that the Spruce(TM) Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer is Now Open for Enrollment

Canada NewsWire August 1, 2013

OncoGenex to Webcast Discussion of Clinical Development Program and Second Quarter 2013 Financial Results on August 8, 2013

Canada NewsWire July 30, 2013

OncoGenex Announces Completion of Patient Enrollment in the Borealis-1(TM) Trial of OGX-427 in Metastatic Bladder Cancer

PR Newswire July 16, 2013

OncoGenex Announces Completion of Patient Enrollment in the Borealis-1(TM) Trial of OGX-427 in Metastatic Bladder Cancer

Canada NewsWire July 16, 2013

OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference

PR Newswire May 28, 2013

OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference

Canada NewsWire May 28, 2013

OncoGenex Announces Plans for the Initiation of the Cedar(TM) Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer

PR Newswire May 23, 2013

OncoGenex Announces Plans for the Initiation of the Cedar(TM) Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer

Canada NewsWire May 23, 2013

OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting

Canada NewsWire May 22, 2013

OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting

PR Newswire May 22, 2013

OncoGenex Announces Plans for the Initiation of the Rainier(TM) Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer

PR Newswire May 1, 2013

OncoGenex Announces that the Borealis-2(TM) Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment

PR Newswire April 30, 2013

OncoGenex to Webcast Discussion of Clinical Development Program and First Quarter 2013 Financial Results on May 2, 2013

PR Newswire April 25, 2013

OncoGenex to Webcast Discussion of Clinical Development Program and First Quarter 2013 Financial Results on May 2, 2013

Canada NewsWire April 25, 2013